The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares insight into the cAMeLot-2 trial (NCT06852222), a randomized Phase III study evaluating the efficacy of bleximenib, venetoclax, plus azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy. The primary endpoints of the study are complete response (CR) and overall survival (OS), with secondary endpoints including duration of CR and safety. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
